

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Valsartan and Amlodipine Tablets (I) (80mg:5mg) from the National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation.

Valsartan and Amlodipine Tablets (I) is mainly used in treatment of primary hypertension (high blood pressure) and for patients whose blood pressure cannot be adequately controlled by a single medication. Hypertension is a common chronic disease. Valsartan and Amlodipine Tablets (I) is the only single-piece compound antihypertensive drug included in the National Essential Drug List of China (國家基本藥物目錄), and is also the first approved single-piece compound solid preparation being developed by the Group. Single-piece compound preparation has become a new trend in treatment of hypertension because it reduces the quantities of medicines, provides convenience of use and can improve treatment compliance and efficacy.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 26 September 2022

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.